WELCOME TO MEDSHADOW. WE'VE UPDATED OUR LOOK!

FDA Chief Wants Doctor Education on Opioid Prescribing

FDA Chief Wants Doctor Education on Opioid Prescribing

In its latest move to curb the prescription opioid abuse epidemic, the FDA wants drugmakers to provide education programs on opioid and managing pain and responsible ways of using opioids to doctors and other healthcare professionals.

FDA Commissioner Scott Gottlieb, speaking Monday at the start of a 2-day meeting on the impact of abuse-resistant opioids, said that the training would apply to immediate-release opioids, which account for 90% of the 200 million opioid prescriptions he says are written each year. Most of the opioids that have abuse-deterrent properties — which make them difficult to inject or snort — are extended-release versions.

“The new training will be aimed at making sure providers who write prescriptions for the IR opioids are doing so for properly indicated patients, and under appropriate clinical circumstances,” he said. He added that the training would also look at non-pharmacological methods and non-opioid drugs to deal with pain.

Gottlieb also said the FDA will survey physicians to find out their views on abuse-deterrent opioids, since he is concerned many of them may mistakenly believe that these drugs are somehow less likely to lead to addiction. “Patients can still become addicted to opioid products with abuse-deterrent features,” he noted.

In an interview with NBC News, Gottlieb said that opioid prescriptions should be written for a shorter period of time. “I believe there are still too many 30-day prescriptions being written for conditions like dental procedures or minor surgery, which should require very short-term use, if they require an opioid prescription at all,” he told the network.

The FDA meeting follows last week’s announcement from Endo International that it will comply with the agency’s request to remove its extended-release, abuse-deterrent opioid, Opana ER, from the market.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x